correct. People need to distinguish the products and mnkd has a huge shadow over it because of pfizer's old product. People do compare it and so does the street.
Jefferies initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating and a price target of $10.00. Analyst Shaunak Deepak said he was taking a contrarian stance ahead of Afrezza launch. He sees peak Afrezza sales of $3.2 billion.
"MNKD is off 33% since the Afrezza approval, reflecting negative Street sentiment about the Sanofi partnership and upcoming launch. Key concerns include docs not adopting Afrezza as a first-line insulin, aggressive counter-detailing from Novo and Lilly to protect their stake in the $6b+ mealtime insulin market, and a bad track record with the only other approved inhaled insulin, Exubera," said Deepak.
"We believe Afrezza could address a major unmet need among patients poorly controlled with oral drugs that have not advanced to injectable agents. Surveys of insulin non-adherence suggest a not insubstantial portion of patients reject insulin due to reluctance to take shots. Accounting for other factors that influence patient avoidance of insulin, we believe Afrezza could be used as a first-line insulin for almost 8% of type 2 patients failing oral drugs, worth $1.6b in peak U.S. sales. We believe Sanofi would promote Afrezza as a first-line insulin to gain and retain patients for its $8b+ insulin franchise," he continued.
"While Afrezza has shown non-inferiority to Novolog as a mealtime add-on in both type 1 and type 2 diabetics, we believe the significantly better A1c reductions with Novolog will be a challenge for marketing Afrezza. Compounding this is the Street’s memory of Exubera as a flop associated with lung cancer. We believe some patients only on basal insulin will be attracted to Afrezza’s benefits in hypoglycemia and weight gain, while some current mealtime insulin users will be drawn to reductions in injection burden and the whistle-like delivery device, which is more discrete than Exubera’s. We expect modest 3% and 6% penetration among type 1 and type 2 patients already on insulin, contributing $200m and $650m in U.S. sal
yes please- As a user have you felt any side effects that pertain to hyped up risks associated with afrezza? Did you cough in the beginning, a lot, and did it subside?
What is the sensation you get when you inhale the medicine, can you describe it?
In your experience, how would you describe the medicine as compared tot he other leading insulin injections, besides the fact that it is inhaled? Is the onset really faster? Also the exit?
Did you gain weight ? Do you feel it can be safe for children ? (I know subjective )
Thank you for your answers. I am not diabetic, however I am an investor and I do believe in the possibilities of such a product, even if pfizer's product failed.
in the week of 8/11 was shorts fueling the fire.
So I have a serious question for all
Do the shorts cover or short more?
I am not looking for a squeeze as some hope, but overall does this make a good buy ?
I too am not a a registered user, but I found this interesting UKMi comment
"Afrezza® is currently in Phase III development in the UK and US. It is predicted for launch in the UK in 2015."
wow.. you have better luck than me. She doesn't call me; but I guess it's ok as long as she is in in good spirits.